157 related articles for article (PubMed ID: 34910356)
41. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
Katogiannis K; Thymis J; Kousathana F; Pavlidis G; Korakas E; Kountouri A; Balampanis K; Prentza V; Kostelli G; Michalopoulou H; Tsilivarakis D; Lambadiari V; Ikonomidis I
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541121
[No Abstract] [Full Text] [Related]
42. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
Zueger PM; Schultz NM; Lee TA
Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
[TBL] [Abstract][Full Text] [Related]
43. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
Scheen AJ; Paquot N
Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
[TBL] [Abstract][Full Text] [Related]
44. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
45. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Gordon M; Meagher P; Connelly KA
Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
[TBL] [Abstract][Full Text] [Related]
46. Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
Amici F; Ciarlo C; Abumusallam J; Kravitz M; Weber AR; Meister H; Li Z
J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):53-60. PubMed ID: 38484469
[TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Shah D; Risebrough NA; Perdrizet J; Iyer NN; Gamble C; Dang-Tan T
Clinicoecon Outcomes Res; 2018; 10():791-803. PubMed ID: 30532570
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Salem A; Men P; Ramos M; Zhang YJ; Ustyugova A; Lamotte M
J Comp Eff Res; 2021 Apr; 10(6):469-480. PubMed ID: 33576249
[No Abstract] [Full Text] [Related]
49. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
[TBL] [Abstract][Full Text] [Related]
50. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
[TBL] [Abstract][Full Text] [Related]
51. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
53. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
[TBL] [Abstract][Full Text] [Related]
54. Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Reifsnider OS; Tafazzoli A; Linden S; Ishak J; Rakonczai P; Stargardter M; Kuti E
J Am Heart Assoc; 2024 Feb; 13(4):e029042. PubMed ID: 38362909
[TBL] [Abstract][Full Text] [Related]
55. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
57. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
[TBL] [Abstract][Full Text] [Related]
58. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Scheen AJ; Wallemacq C; Jandrain B; Ernest P
Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791
[TBL] [Abstract][Full Text] [Related]
59. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
Rossello X; Yellon DM
Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Eliasson B; Ericsson Å; Fridhammar A; Nilsson A; Persson S; Chubb B
Pharmacoecon Open; 2022 May; 6(3):343-354. PubMed ID: 35064550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
